van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.
Jakko Van Ingen, MD, PhD
Advertisement
Professor of Clinical Microbiology at Radbound University Medical Center
Articles by Jakko Van Ingen, MD, PhD
van Ingen, of Radboud University Medical Center discusses data showing add-on ALIS improved durable culture conversion in newly diagnosed MAC lung disease.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Conference Preview: 2026 GOLD International COPD Conference
2
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
3
Pegcetacoplan Sustains Proteinuria Reduction at 76 Weeks in Adolescents
4
7 Pulmonology Headlines You Missed in October
5